Myocet liposomal is a cancer medicine for use with cyclophosphamide (another cancer medicine) to treat women with metastatic breast cancer. ‘Metastatic’ means that the cancer has spread to other parts of the body. Myocet liposomal contains the active substance doxorubicin.
Therapeutic Indication
Myocet liposomal, in combination with cyclophosphamide, is indicated for the first\-line treatment of metastatic breast cancer in adult women.
Therapeutic Area (MeSH)
ATC Code
L01DB01
ATC Item
N/A
Pharmacotherapeutic Group
Antineoplastic agents
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| doxorubicin hydrochloride | N/A | doxorubicin hydrochloride |
EMA Name
Myocet liposomal (previously Myocet)
Medicine Name
Myocet liposomal (previously Myocet)
Aliases
N/ANo risk management plan link.
